E-Mail
Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the British variant ), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University s Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.
The virus variant was labelled Variant of Concern 202012/01 by Public Health England (PHE), an agency of the UK Department of Health and Social Care, in a publication on December 21, 2020, after it was found to have spread rapidly within the UK, and the PHE assessed that this variant has a substantially increased transmissibility compared with other coronavirus variants. This variant has also been identified in the U.S. in several states, and the Centers for Disease Control confirms that this variant spreads more easily and quickly than other variants.
Study: Coronavirus Activates Antibodies From Previous Coronavirus Infections
This discovery could help in developing new therapeutic treatments.
Individuals who have contracted the coronavirus have been found to rely on antibodies created during infections from earlier coronaviruses to help fight the disease, according to a new study conducted by Northern Arizona University and the Translational Genomics Research Institute (TGen).
The research, published in the journal
Cell Reports Medicine, noted that the coronavirus isn’t humanity’s first run-in with a coronavirus. In fact, before SARS-CoV-2 the virus that causes COVID-19 humans have been confronted with at least six other types of coronaviruses.